1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

China Approves Two Sanofi-Licensed Breakthrough Medicines for Rare and Cardiovascular Diseases

19 Jan 2026
Admin
News Article

China Approves Two Sanofi-Licensed Breakthrough Medicines for Rare and Cardiovascular Diseases

China’s National Medical Products Administration (NMPA) has approved two innovative Sanofi-licensed therapies, expanding options for patients with serious unmet medical needs.

The approvals cover Myqorzo (aficamten) for obstructive hypertrophic cardiomyopathy and Redemplo (plozasiran) for familial chylomicronaemia syndrome.

What Was Approved—and Why It Matters?

Sanofi will bring both medicines to patients across Greater China, reinforcing its long-term innovation strategy in the region.

According to Sanofi, both therapies address complex, underserved conditions with limited treatment options.

Myqorzo (Aficamten): A New Option for oHCM

Myqorzo is a selective cardiac myosin inhibitor designed to treat symptomatic obstructive hypertrophic cardiomyopathy (oHCM).

oHCM is the most common inherited cardiovascular disorder, caused by abnormal thickening of the heart muscle.

This thickening restricts blood flow, reduces exercise capacity, and increases the risk of serious cardiac events.

Clinical Basis for Approval

Approval based on the SEQUOIA-HCM Phase 3 trial
Demonstrated improvement in functional capacity and symptom relief
Targets myocardial hypercontractility at its source

Regulatory Status Highlights

Approved in the US and China
Breakthrough therapy and orphan drug designations in the US
Positive CHMP opinion in the EU, with final decision expected in Q1 2026

Sanofi holds exclusive Greater China rights, acquired through Corxel Pharmaceuticals.

Redemplo (Plozasiran): Targeting Extreme Triglycerides

Redemplo is a small-interfering RNA (siRNA) therapy for familial chylomicronaemia syndrome (FCS). FCS is a rare, life-threatening disease marked by triglyceride levels exceeding 880 mg/dL. These extreme levels can cause acute pancreatitis, chronic pain, diabetes, and liver disease.

How Redemplo Works?

Silences production of apoC-III in the liver
Improves triglyceride breakdown and clearance
Delivers sustained triglyceride reduction

Clinical and Regulatory Profile

Approval based on the PALISADE Phase 3 trial
Approved in the US, Canada, and China
EU regulatory review is ongoing
Breakthrough, fast track, and orphan designations across major markets

Sanofi acquired Greater China rights in August 2025 from Visirna Therapeutics.

The Bigger Picture

These approvals strengthen Sanofi’s presence in rare diseases and cardiology within China. They also reflect China’s growing openness to first-in-class and advanced RNA-based therapies.

Sanofi continues positioning itself as an R&D-driven, AI-powered biopharma, focused on high-impact innovation.